June 16 – 18, 2013
| Sunday, June 16 MIT Faculty Club, 50 Memorial Drive, Building E52, 6th Floor, Cambridge, MA | |
|---|---|
| 5:30 – 6:30 | Registration and cocktails |
| 6:30 – 8:30 | Welcome Dinner Welcome Remarks Dean David Schmittlein, MIT Sloan School of Management Opportunities and Challenges in Cancer Drug Development Anna Protopapas, Millennium: The Takeda Oncology Company |
| Monday, June 17 Wong Auditorium, 70 Memorial Drive, Building E51, Cambridge, MA (entrance at corner of Wadsworth and Amherst Streets) | |
|---|---|
| 8:00 – 8:30 | Continental Breakfast |
| 8:30 – 9:15 | Welcome Remarks Daniel Goroff, Alfred P. Sloan Foundation; Thomas Kalil, White House Office of Science and Technology Policy; J. Leonard Lichtenfeld, American Cancer Society; Larry Nagahara, NCI |
| 9:15 – 10:00 | Background, and Conference Objectives Andrew W. Lo, MIT |
| 10:00 – 10:15 | Break |
| 10:15 – 12:15 | Session 1: Scientific and Engineering Challenges Parag Mallick*, Stanford and Nicholas F. Marko*, MD Anderson Lewis C. Cantley, Weill Cornell and Agios;Larry Norton, Memorial Sloan-Kettering; Phillip A. Sharp, MIT; Thomas Unger, Pfizer |
| 12:30 – 2:30 | Lunch and Speaker: Robert A. Weinberg, Whitehead Institute |
| 2:30 – 4:00 | Session 2: New Business Models A Gary Pisano*, Harvard Business School Jim Broderick, Morgenthaler Ventures; Gigi Hirsch, MIT NEWDIGS; Fiona Murray, MIT; J. Marty Tenenbaum, CancerCommons |
| 4:00 – 4:30 | Break |
| 4:30 – 6:00 | Session 3: Financing Structure, Marketing, and Investor Perspectives Douglas A. Dachille*, First Principles Capital Management Britt Canady, Bank of America Merrill Lynch; Michael Fusco, Morgan Stanley Peter Hancock, AIG; Kira Rosoff, Deutsche Bank |
| 6:00 – 6:30 | Day 1 Conference Wrap-Up |
| 6:30 – 8:30 | Dinner Location: MIT Media Lab, 75 Amherst Street, 6th Floor, Building E14, Cambridge, MA |
| Tuesday, June 18 Wong Auditorium, 70 Memorial Drive, Building E51, Cambridge, MA (entrance at corner of Wadsworth and Amherst Streets) | |
|---|---|
| 8:00 – 9:00 | Continental Breakfast |
| 9:00 – 10:30 | Session 4: Government, Healthcare Reform, and Non-Profits Clifford Gibbons*, Gibbons & Co. Douglas Criscitello, Grant Thornton; Ora Dar, Israeli Life Sciences Fund; Jonathan Gruber, MIT; Robert O’Neill, FDA; John S. Parker, SAIC |
| 10:30 – 11:00 | Break |
| 11:00 – 12:30 | Session 5: New Business Models B Andrew W. Lo*, MIT Edward Benz, Dana-Farber Cancer Institute; Ansbert Gadicke, MPM Capital; Frank McCormick, UCSF; John McKew, National Institutes of Health, NCATS, TRND; Alastair Wood, Symphony Capital LLC |
| 12:30 – 2:00 | Lunch and Speaker: Robert Langer, MIT |
| 2:00 – 3:30 | Session 6: Technology Licensing and Intellectual Property Issues Lita Nelsen*, MIT TLO and O. Prem Das*, Dana Farber TLO Jeb Keiper, GlaxoSmithKline; Vikas P. Sukhatme, Beth Israel Deaconess Medical Center; Teri Willey, Mount Sinai Medical Center |
| 3:30 – 3:45 | Break |
| 3:45 – 5:15 | Session 7: Credit Models and Debt Ratings Roger Stein*, Moody’s and MIT LFE John Hull, UToronto; Bruce N. Lehmann, UCSD; Robert C. Merton, MIT; Henry Shilling, Moody’s Investor Services; Chip Wallach, Bank of America Merrill Lynch |
| 5:15 – 6:00 | Day 2 Conference Wrap-Up |
*Moderator and Session Chair